Common stock, 0.0001 par value, 250,000,000 shares authorized at march 31, 2026 and december 31, 2025 9,277,825 and 4,574,983 shares issued at march 31, 2026 and december 31, 2025, respectively 9,277,819 and 4,574,977 shares outstanding at march 31, 2026 and december 31, 2025, respectively
929
459
320
241
Additional paid-in capital
142,935,443
142,933,260
138,155,394
136,612,043
Accumulated deficit
-143,276,414
-139,719,999
-136,952,351
-133,223,223
Total ensysce biosciences, inc. stockholders equity (deficit)
-340,042
3,213,720
1,203,363
3,389,061
Noncontrolling interests in stockholders equity (deficit)
-328,970
-328,970
-328,649
-328,649
Total stockholders equity (deficit)
-669,012
2,884,750
874,714
3,060,412
Total liabilities and stockholders equity (deficit)
2,167,803
7,452,479
3,179,464
5,574,455
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.